{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:03:53Z","timestamp":1789617833077,"version":"build-2803163510"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T00:00:00Z","timestamp":1256774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Persistent high\u2010titre inhibitors after immune tolerance induction (ITI) increase the risks of haemorrhage and arthropathy, resulting in high morbidity and mortality. Long\u2010term prophylaxis with bypassing agents may avert these risks. This study was performed to assess the effectiveness and safety of early prophylaxis with FEIBA in preventing bleeding and joint damage after failed ITI. Seven paediatric patients proceeded immediately after failed ITI to long\u2010term FEIBA prophylaxis at 60\u2013100\u2003IU\u2003kg<jats:sup>\u22121<\/jats:sup> dosages and various dosing intervals depending upon bleeding tendency. Bleeding episodes and joint status were assessed. Thrombin generation assays (TGA) were also used to gauge treatment response. FEIBA prophylaxis was commenced at a median age of 6.0\u2003years (range, 1.5\u201311.8\u2003years) and continued for a median duration of 6.9\u2003years (range, 0.8\u201317.1\u2003years). The mean annual incidence of joint bleeding was 1.5 episodes per year with a 95% CI of 0.7\u20133.0\u2003episodes per year. Muscle bleeding incidence was 0.9 episodes per year (CI, 0.6\u20131.2 episodes per year). No patient experienced major joint damage during prophylaxis. Median Pettersson and orthopaedic joint scores at the last follow\u2010up evaluation were 4 (range, 0\u201312) and 2 (range, 0\u20134) respectively. Endogenous thrombin potential (ETP) measured by TGA exceeded 80% of normal after FEIBA infusion in the majority of the patients. Between regular prophylactic infusions, mean trough ETP equalled 2.6 fold of the inhibitor plasma control mean. FEIBA prophylaxis was well\u2010tolerated without serious thrombotic or other complications. The only adverse event involved venous access. Therefore early long\u2010term FEIBA prophylaxis is valuable in controlling bleeding and preserving joint integrity in young patients failing ITI.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.02116.x","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T03:22:48Z","timestamp":1256872968000},"page":"90-100","source":"Crossref","is-referenced-by-count":41,"title":["Early long\u2010term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series"],"prefix":"10.1111","volume":"16","author":[{"given":"C. ESCURIOLA","family":"ETTINGSHAUSEN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"KREUZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,29]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1457"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01369.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01518.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01370.x"},{"issue":"3","key":"e_1_2_7_6_2","first-page":"54","article-title":"The role of VWF in immune tolerance induction \u2013 the German experience","volume":"10","author":"Escuriola\u2010Ettingshausen C","year":"2004","journal-title":"Haemophilia"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167660.30886.e9"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0941"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440413.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01463.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2337"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.17.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01379.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01380.x"},{"key":"e_1_2_7_16_2","first-page":"1140","article-title":"Efficacy and safety of factor VIII inhibitor bypass activity (Feiba) for long\u2010term prophylaxis in patients with high\u2010responding inhibitors","volume":"96","author":"Kreuz W","year":"2000","journal-title":"Blood"},{"key":"e_1_2_7_17_2","first-page":"P1628","article-title":"Long\u2010term prophylaxis with FEIBA\u00ae in patients with high\u2010responding inhibitors","volume":"1","author":"Escuriola\u2010Ettingshausen C","year":"2003","journal-title":"J Thromb Haemost"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00771.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01382.x"},{"issue":"1","key":"e_1_2_7_20_2","first-page":"P2036","article-title":"Anamnestic responses in hemophilia patients with inhibitors on continuous prophylaxis with factor eight inhibitor bypassing activity, vapor heated (FEIBA VH)","volume":"3","author":"Ewing N","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"1","key":"e_1_2_7_21_2","first-page":"P0838","article-title":"Long\u2010term clinical experience with FEIBA VH in hemophilia patients with inhibitors","volume":"3","author":"Saxena K","year":"2005","journal-title":"J Thromb Haemost"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01143.x"},{"issue":"2","key":"e_1_2_7_23_2","first-page":"14 PO 371","article-title":"FEIBA prophylaxis in hemophilia A patient with inhibitors decreases bleeding episodes, improves joint function and enhance quality of life","volume":"12","author":"Cheng S","year":"2006","journal-title":"Haemophilia"},{"issue":"2","key":"e_1_2_7_24_2","first-page":"14 PO 399","article-title":"Can long\u2010term prophylaxis with APCC improve the bleeding rate and quality of life of frequently bleeding haemophiliacs with inhibitor?","volume":"12","author":"Lambert T","year":"2006","journal-title":"Haemophilia"},{"issue":"2","key":"e_1_2_7_25_2","first-page":"14 PO 424","article-title":"aPCC (FEIBA) home therapy retrospective survey in long\u2010term secondary prophylaxis on hemophilia A patients with factor VIII inhibitor","volume":"12","author":"Schino M","year":"2006","journal-title":"Haemophilia"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01442.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20751"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01284.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01346.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-198006000-00018"},{"key":"e_1_2_7_31_2","first-page":"3","article-title":"Prophylaxis: musculoskeletal evaluation","volume":"30","author":"Gilbert MS","year":"1993","journal-title":"Semin Hematol"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00450.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00936.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01403.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00546.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02580.x"},{"key":"e_1_2_7_37_2","first-page":"489","article-title":"The impact of prophylaxis on children with severe haemophilia","volume":"8","author":"Panicker J","year":"2002","journal-title":"Haemophilia"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00630.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00560.x"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01915.x"},{"issue":"3","key":"e_1_2_7_41_2","first-page":"114","article-title":"Evaluation of FEIBA for prophylaxis in patients with inhibitors","volume":"10","author":"Ewenstein B","year":"2004","journal-title":"Haemophilia"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00934.x"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1159\/000071636"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1159\/000071637"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-10-0706"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00935.x"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01594.x"},{"issue":"2","key":"e_1_2_7_48_2","first-page":"P\u2010T\u2010158","article-title":"Anamnesis in patients with hemophilia and inhibitors who receive activated prothrombin complex concentrates for prophylaxis","volume":"5","author":"Ewing NP","year":"2007","journal-title":"J Thromb Haemost"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.02116.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.02116.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T03:54:41Z","timestamp":1698638081000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.02116.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,29]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1365-2516.2009.02116.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02116.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,29]]}}}